Redx sells another asset to keep the lights on
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Boehringer splashes the cash in Nash
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
A Botox filler for Abbvie's Humira-shaped hole
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Rich recognition finally arrives for Array
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
Vertex’s second transformation: Duchenne time
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Merck sees potential in Peloton
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Aegerion’s poisoned chalice gives Amryt some distraction therapy
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.